Analysts Set OnKure Therapeutics, Inc. (NASDAQ:OKUR) Target Price at $32.33

Shares of OnKure Therapeutics, Inc. (NASDAQ:OKUR) have received a consensus recommendation of “Moderate Buy” from the seven ratings firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $32.3333.

OKUR has been the subject of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $34.00 price target on shares of OnKure Therapeutics in a report on Tuesday, August 26th. Zacks Research cut shares of OnKure Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 13th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of OnKure Therapeutics in a report on Wednesday, October 8th. Finally, Wall Street Zen upgraded shares of OnKure Therapeutics to a “sell” rating in a research note on Saturday.

OnKure Therapeutics Trading Down 5.2%

NASDAQ OKUR opened at $3.10 on Friday. The company has a fifty day simple moving average of $2.82 and a two-hundred day simple moving average of $2.56. The stock has a market cap of $41.94 million, a P/E ratio of -0.65 and a beta of 0.46. OnKure Therapeutics has a 12-month low of $1.70 and a 12-month high of $17.74.

OnKure Therapeutics (NASDAQ:OKUR) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($1.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.23) by $0.09. As a group, sell-side analysts forecast that OnKure Therapeutics will post -4.05 earnings per share for the current year.

Institutional Trading of OnKure Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in OKUR. XTX Topco Ltd acquired a new stake in shares of OnKure Therapeutics in the second quarter worth $25,000. Bailard Inc. acquired a new stake in shares of OnKure Therapeutics in the second quarter worth $34,000. ADAR1 Capital Management LLC acquired a new stake in shares of OnKure Therapeutics in the first quarter worth $43,000. Rangeley Capital LLC acquired a new stake in shares of OnKure Therapeutics in the second quarter worth $71,000. Finally, Highbridge Capital Management LLC increased its stake in shares of OnKure Therapeutics by 51.2% in the second quarter. Highbridge Capital Management LLC now owns 663,607 shares of the company’s stock worth $1,586,000 after acquiring an additional 224,810 shares during the period. Institutional investors and hedge funds own 90.98% of the company’s stock.

OnKure Therapeutics Company Profile

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.